8 February 2018 - - Austin, Texas-based diagnostic tests and bio-analytical solutions specialist Verm, Inc. (NASDAQ: VRML) has been granted two new US patents that significantly expand coverage for its core technologies, OVA1 and Overa, the company said.
The first patent, entitled "Biomarker for ovarian cancer CTAP3-related proteins," describes and claims panels of biomarkers associated with ovarian cancer.
The second patent, entitled "Predictive biomarkers for ovarian cancer," describes and claims sets of reagents used to measure biomarkers associated with ovarian cancer.
Verm (NASDAQ: VRML) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests and bio-analytical solutions that help physicians diagnose, treat and improve gynecologic health outcomes for women.
The company's initial in vitro diagnostic test, OVA1, was the first FDA-cleared, protein-based In Vitro Diagnostic Multivariate Index Assay and represented a new class of software-based liquid biopsy in vitro diagnostics.
In March 2016, Verm received FDA clearance for Overa, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use.